<DOC>
	<DOCNO>NCT01042288</DOCNO>
	<brief_summary>The purpose multicenter , Phase II trial examine role well-tolerated novel agent , panitumumab , combination modern platinum doublet regimen use carboplatin pemetrexed , patient advance non-squamous wild type K-ras non-small-cell lung cancer ( NSCLC ) . If treatment prove well tolerate associate efficacy , would provide rationale randomized study .</brief_summary>
	<brief_title>Carboplatin , Pemetrexed , Panitumumab Patients With Advanced Non-Squamous K-ras Wild Type NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age ≥18 year . 2 . Histologically confirm nonsquamous NSCLC ( squamous cell histology ineligible ) . Cytologic specimen obtain brushing , washing needle aspiration define lesion acceptable . Sputum cytology alone acceptable . Mixed tumor small cell element eligible . 3 . Newly diagnose unresectable stage IIIB stage IV disease . Patients stage IIIB disease ineligible combine modality therapy ( i.e. , pleural effusion , pericardial effusion , etc. ) . 4 . At least one unidimensionally measurable lesion definable magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan . Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . 5 . Demonstration Kras wild type archive tumor tissue . Tissue must available test result previous Kras test must available time registration . 6 . No prior antineoplastic chemotherapy metastatic lung cancer . Patients may receive adjuvant treatment stage I , II III disease . 7 . For patient previous radiotherapy definitive therapy locally advance NSCLC , recurrence must outside original radiation therapy port . Radiation therapy must complete four week prior study entry . Previous radiation must cover &lt; 30 % marrow bear area . 8 . Full recovery surgery patient undergone thoracotomy . Patients start protocol treatment least three week operative procedure . 9 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 10 . Life expectancy ≥ 12 week . 11 . Normal bone marrow function within 7 day prior initial treatment define : absolute neutrophil count ( ANC ) ≥1500/µL platelet ≥100,000/µL hemoglobin ≥8.0 g/dL . Patients may receive transfusion erythropoietin maintain exceed level . 12 . Normal hepatic function define : bilirubin ≤1.5 x institutional upper limit normal ( ULN ) . transaminase ≤2.5 x institutional ULN . In presence know hepatic metastasis , transaminase may ≤5 x institutional ULN . 13 . Normal renal function within 7 day prior initial treatment define : serum creatinine &lt; 2.0 mg/dL estimate creatinine clearance ( CrCl ) ≥ 45 mL/min calculate CockcroftGault method . 14 . Normal metabolic function follow : • Magnesium ≥ institutional low limit normal ( LLN ) 15 . The ability take folic acid , vitamin B12 , dexamethasone accord protocol . 16 . The ability interrupt nonsteroidal antiinflammatory drug ( NSAIDs ) 2 day ( 5 day longacting NSAIDs ) , day , 2 day follow administration pemetrexed . 17 . Negative serum urine pregnancy test within 7 day prior initial study treatment . 18 . Agreement woman childbearing potential ( WOCBP ) men use adequate contraception ( hormonal barrier method birth control ; abstinence ) prevent contraception treatment minimum 6 month last study treatment . 19 . Willingness ability comply study followup procedure . 20 . Ability understand nature study give write informed consent . 1 . NSCLC squamous cell histology . 2 . History invasive cancer treat within previous 5 year exception disease study , curatively treat non melanoma skin cancer carcinoma situ cervix . 3 . Prior therapy specifically directly target EGFR pathway ( e.g. , cetuximab , gefitinib , erlotinib , lapatinib ) . 4 . Active brain meningeal metastasis . Patients must complete previous radiotherapy least four week prior study entry recover toxicity associate radiotherapy . Patients must ongoing requirement must discontinue corticosteroid . 5 . Pregnancy breastfeed . 6 . A serious active infection time treatment serious underlie medical condition would impair ability patient receive protocol treatment . 7 . Acute hepatitis know human immunodeficiency virus ( HIV ) infection . 8 . Presence third space fluid clinically significant control drainage . 9 . History interstitial lung disease ( e.g. , pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan ) . 10 . History medical psychiatric condition laboratory abnormality opinion investigator may increase risk associate study participation investigational product ( ) administration may interfere interpretation result . 11 . Prior severe infusion reaction monoclonal antibody history allergic reaction attribute compound similar chemical biologic composition agent use study ( e.g. , carboplatin , pemetrexed ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Non-Small-Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Vectibix</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Alimta</keyword>
	<keyword>Carboplatin</keyword>
</DOC>